Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 OCT 19 ... drug, Plicera™ (afegostat tartrate), in treatment-naive adult patients with type 1 Gaucher disease. Two dose regimens of Plicera (225 mg three days on/four days off and seven days ...
2009 OCT 19 ... New research, 'Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent,' is the subject of a report. ...
2009 NOV 16 ... the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease. Priority Review designation is given to drugs that offer major advances in ...
2009 SEP 21 ... plant cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease. Gaucher disease is a lysosomal storage disorder ...
2009 NOV 2 ... global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the ...
2009 OCT 5 ... can reach patients as quickly as possible. I want to express my deep appreciation to the Gaucher and Fabry communities for their support of the existing product conservation guidelines ... The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's ...
2009 NOV 2 ... global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. Genzyme is accelerating this development program in an effort to bring this ...
2009 OCT 12 ... in the Journal of Inherited Metabolic Disease, "We report a female patient with Gaucher disease (GD) type I on ERT (imiglucerase) for 5 years, which led to a significant general ...
2009 NOV 16 ... report 'Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.' "Data from the International ...
2009 NOV 1 ... TOP-LINE RESULTS FROM ITS PHASE III CLINICAL TRIAL OF UPLYSO™ FOR THE TREATMENT OF GAUCHER DISEASE Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced positive top-line results ...
2009 NOV 9 ... its lead product candidate, UPLYSO (prGCD), to be used in enzyme replacement therapy for Gaucher disease, a rare and serious lysosomal storage disorder in humans with severe and debilitating ...
2009 SEP 28 ... plant-cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease. The trial enrolled a total of 31 patients across Europe, North America, South America, ...
2009 OCT 5 ... its lead product candidate, UPLYSO (prGCD), to be used in enzyme replacement therapy for Gaucher disease, a rare and serious lysosomal storage disorder in humans with severe and debilitating ...
2009 NOV 23 ... St., New York, NY 10013, USA. Keywords: City:Mansoura, Country:Egypt, Gaucher Disease, Hematology, Magnetic Resonance, Neuroradiology. This article was prepared ...
2009 NOV 16 ... of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain the ...
2009 NOV 23 ... activity reflects the presence of lipid-laden macrophages in patients with Gaucher disease." "CHIT1 activity can be conveniently measured using fluorogenic ...
2009 NOV 2 ... of Health researcher has found that carriers of a rare, genetic condition called Gaucher disease face a risk of developing Parkinson's disease more than five times greater than the ...
Subject: NIH/National Human Genome Research Institute
